Search All News
Dr. Jeffrey Bruce: "This new approach has the potential to transform treatment for patients with brain cancer, where the outlook for survival remains very poor."
Three multi-disciplinary research teams have been awarded the 2022 Irving Multi-PI Planning Grant to fuel innovative research and treatment.
Dr. Andrew Lassman: "These trials transformed our understanding of the clinical behavior of molecularly defined gliomas and contributed to the classification of gliomas used globally today."
- March 28, 2022
A new study led by Dr. Andrew Lassman addresses safety and efficacy of infigratinib, a fibroblast growth factor receptor (FGFR)-tyrosine kinase inhibitor, for patients with recurrent glioblastomas.
- July 8, 2021
New clinical trial studies the application of focused ultrasound technique to deliver chemotherapy in patients with DIPG, an aggressive type of brain cancer.
Source:CUIMC NewsroomJanuary 11, 2021
A study, led by HICCC members, has found that up to 20% of glioblastomas—an aggressive brain cancer—are fueled by overactive mitochondria and may be treatable with drugs currently in clinical trials.